Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine. Lopinavir/ritonavir is unlikely to inhibit OATs at clinically relevant concentrations. However, caution should be exercised as both drugs have risks of QT prolongation and/or TdP on the CredibleMeds.org website (possible risk for lopinavir; known risk for ciprofloxacin). If coadministration is necessary, clinical monitoring including ECG assessment is recommended.
View all available interactions with
Lopinavir/ritonavir (LPV/r) by clicking